
Dexmedetomidine, a promising anesthesia adjunct, showed significant benefits in patients undergoing pituitary adenoma transsphenoidal resection. A systematic review of six clinical trials revealed dexmedetomidine's ability to reduce heart rate and mean arterial blood pressure during surgery and after extubation, suggesting improved hemodynamic stability. Additionally, it lowered blood loss and surgical duration without affecting propofol dosage or extubation time. These findings highlight dexmedetomidine's potential to enhance outcomes for this specific surgical group.
Like
Save
Share